Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 2/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 4/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114291 | 0.82 | CNR1 (0.35) | CNR1TNFHDAC2HDAC8HDAC6 | |
| SCHEMBL5119433 | 0.76 | HTR5A (0.47) | SMARCA2SMARCA4PBRM1ALDH1A1TP53 | |
| SCHEMBL5114490 | 0.76 | PGR (0.38) | — | |
| SCHEMBL5111570 | 0.68 | HTR5A (0.46) | SMARCA2SMARCA4PBRM1TP53 | |
| SCHEMBL5117969 | 0.68 | PBRM1 (0.41) | SMARCA2SMARCA4PBRM1ALDH1A1TP53 | |
| SCHEMBL8249643 | 0.66 | KDM4E (0.46) | HDAC2HDAC8HDAC6ALDH1A1TP53 | |
| SCHEMBL5118402 | 0.65 | PBRM1 (0.38) | SMARCA2SMARCA4PBRM1ALDH1A1TP53 | |
| SCHEMBL11040506 | 0.64 | CA2 (0.47) | SMARCA2SMARCA4PBRM1ALDH1A1TP53 | |
| SCHEMBL30525239 | 0.63 | MAOB (0.36) | — | |
| SCHEMBL30525241 | 0.63 | ADORA2A (0.36) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442696-B2 | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses | LIGAND PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070197520-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES | LIGAND PHARMACEUTICALS INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2006010142-A2 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197520-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES | NR3C2, MC2R, NR3C1 | SMARCA2 3346/4885SMARCA4 3200/4885PBRM1 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.